These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 15727148

  • 1. [Modern fluoroquinolones (ciprofoxacin, levofloxacin) and the treatment of skin and soft tissue infections].
    Iakovlev VP, Svetukhin AM, Blatun LA, Ukhin SA.
    Antibiot Khimioter; 2004; 49(8-9):57-65. PubMed ID: 15727148
    [No Abstract] [Full Text] [Related]

  • 2. [Levofloxacin in complex therapy of patients with skin and soft tissue infections].
    Blatun LA, Terekhova RP.
    Antibiot Khimioter; 2008; 53(9-10):32-5. PubMed ID: 19441647
    [No Abstract] [Full Text] [Related]

  • 3. [Efficacy and safety of levofloxacin in low respiratory tract infection].
    Zubkov MN.
    Antibiot Khimioter; 2004; 49(5):31-7. PubMed ID: 15573900
    [No Abstract] [Full Text] [Related]

  • 4. Moxifloxacin: new preparation. A me-too with more cardiac risks.
    Prescrire Int; 2002 Dec; 11(62):168-9. PubMed ID: 12469694
    [Abstract] [Full Text] [Related]

  • 5. Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: double-blind, multicenter, randomized study.
    Tarshis GA, Miskin BM, Jones TM, Champlin J, Wingert KJ, Breen JD, Brown MJ.
    Antimicrob Agents Chemother; 2001 Aug; 45(8):2358-62. PubMed ID: 11451697
    [Abstract] [Full Text] [Related]

  • 6. Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract.
    Langtry HD, Lamb HM.
    Drugs; 1998 Sep; 56(3):487-515. PubMed ID: 9777318
    [Abstract] [Full Text] [Related]

  • 7. Levofloxacin, a broad spectrum anti-infective: from Streptococcus pneumoniae to Pseudomonas aeruginosa.
    Schito AM, Schito GC.
    J Chemother; 2004 Apr; 16 Suppl 2():3-7. PubMed ID: 15255554
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.
    Martin SJ, Jung R, Garvin CG.
    Drug Saf; 2001 Apr; 24(3):199-222. PubMed ID: 11347723
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Multicenter, randomized study comparing levofloxacin and ciprofloxacin for uncomplicated skin and skin structure infections.
    Nichols RL, Smith JW, Gentry LO, Gezon J, Campbell T, Sokol P, Williams RR.
    South Med J; 1997 Dec; 90(12):1193-200. PubMed ID: 9404904
    [Abstract] [Full Text] [Related]

  • 14. Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?
    Ernst ME, Ernst EJ, Klepser ME.
    Am J Health Syst Pharm; 1997 Nov 15; 54(22):2569-84. PubMed ID: 9397218
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Prospects of Levofloxacin Use in Therapy of Patients with Bronchopulmonary Diseases or Skin and Soft Tissue Pyo-Inflammatory Lesions].
    Sokolova VI, Sychev DA, Babarina MB, Zaikov DA.
    Antibiot Khimioter; 2014 Nov 15; 59(11-12):35-9. PubMed ID: 26448992
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.